当前位置:首页 - 行情中心 - 神州细胞-U(688520) - 财务分析 - 利润表

神州细胞-U

(688520)

  

流通市值:220.92亿  总市值:221.96亿
流通股本:4.43亿   总股本:4.45亿

利润表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、营业总收入612,503,357.241,887,349,306.41,379,251,634.17808,075,290.81
营业收入612,503,357.241,887,349,306.41,379,251,634.17808,075,290.81
二、营业总成本454,129,612.341,909,716,643.411,331,517,554.73821,713,792.78
营业成本20,486,151.654,541,484.5340,291,135.325,650,038.36
税金及附加4,041,783.1812,938,168.689,473,874.445,591,686.93
销售费用124,602,499.38436,150,158.25294,471,770.13180,979,669.99
管理费用36,999,229.94149,685,773.4103,140,810.4362,745,735.29
研发费用237,334,271.651,148,170,339.03806,115,168.18497,062,986.72
财务费用30,665,676.59108,230,719.5278,024,796.2549,683,675.49
其中:利息费用30,773,972.47111,521,100.0980,594,047.9250,673,142.93
其中:利息收入1,261,222.397,035,097.255,861,880.024,287,888.65
加:公允价值变动收益--54,052.88-
加:投资收益19,561.182,476,410.842,243,768.612,082,203.44
资产处置收益9,016.38-64,332.7-64,632.7-8,903.25
资产减值损失(新)-390,996.73-42,320,772.83-28,303,541.69-
信用减值损失(新)-561,976.09-1,021,990.84-1,061,811.68401,216.92
其他收益43,760,047.9469,663,626.5137,519,624.6728,636,834.54
营业利润平衡项目0000
四、营业利润201,209,397.586,365,603.9758,121,539.5317,472,849.68
加:营业外收入177,609.441,186,589.5913,444,275.6913,287,733.04
减:营业外支出126,978,045.85404,383,281.36291,949,566.3168,872,729.16
利润总额平衡项目0000
五、利润总额74,408,961.17-396,831,087.8-220,383,751.08-138,112,146.44
六、净利润74,408,961.17-396,831,087.8-220,383,751.08-138,112,146.44
持续经营净利润74,408,961.17-396,831,087.8-220,383,751.08-138,112,146.44
归属于母公司股东的净利润74,197,374.04-396,018,311.08-219,964,027.34-137,857,224.2
少数股东损益211,587.13-812,776.72-419,723.74-254,922.24
(一)基本每股收益0.17-0.89-0.49-0.31
(二)稀释每股收益0.17-0.89-0.49-0.31
八、其他综合收益-17,305.69-29,194.12-67,674.3849,648.68
归属于母公司股东的其他综合收益-17,262.43-29,121.13-67,674.3849,648.68
九、综合收益总额74,391,655.48-396,860,281.92-220,451,425.46-138,062,497.76
归属于母公司股东的综合收益总额74,180,111.61-396,047,432.21-220,031,701.72-137,807,575.52
归属于少数股东的综合收益总额211,543.87-812,849.71-419,723.74-254,922.24
公告日期2024-04-262024-04-132023-10-282023-08-23
审计意见(境内)标准无保留意见
TOP↑